A Phase II Study of SKB571 in Patients With Lung Cancer

This is a multicenter, phase II study. The purpose of this study is to evaluate the safety and preliminary anti-tumor activity of SKB571 in patients with advanced non-small cell lung cancer. Eligible subjects will receive SKB571 monotherapy, until radiographic disease progression, intolerable toxicity, discontinuation of study treatment required by the subject, or other protocol-specified treatment discontinuation criteria, whichever occurs first.

Trial Details

NCT ID
NCT07230405
Phase
PHASE2
Sponsor
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • SKB571 for injection
Locations (sample)
  • Guangzhou, China|23.11667,113.25
  • Zhengzhou, China|34.75778,113.64861

Key Eligibility Criteria

  • Subjects aged 18-75 years at the time of signing the informed consent form
  • Subjects with histologically or cytologically confirmed locally advanced or metastatic NSCLC .
  • Subjects with at least one measurable lesion assessed by the investigator according to RECIST v1.1.
  • Subjects with Eastern Cooperative Oncology Group (ECOG) status score of 0 or 1.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →